The final report from the HORIZONS-AMI trial in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction shows that the early benefits of bivalirudin and paclitaxel-eluting stents are sustained at 3 years. Bivalirudin, thrombus aspiration, and drug-eluting stents might be the new standard of care for primary percutaneous coronary intervention.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Faxon, D. P. Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention. Catheter. Cardiovasc. Interv. doi:10.1002/ccd.23163.
Stone, G. W. et al. Bivalirudin during primary PCI in acute myocardial infarction. N. Engl. J. Med. 358, 2218–2230 (2008).
Mehran, R. et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomized controlled trial. Lancet. 374, 1149–1159 (2009).
Stone, G. W. et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicenter, randomised controlled trial. Lancet. 377, 2193–2204 (2011).
Dangas, G. D. et al. Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction. The HORIZONS-SWITCH analysis. J. Am. Coll. Cardiol. 23, 2309–2316 (2011).
Cohen, M. et al. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. J. Am. Coll. Cardiol. 48, 1346–1354 (2006).
White, H. D. et al. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J. Am. Coll. Cardiol. 51, 1734–1741 (2008).
Dangas, G. D. et al. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation. 123, 1745–1756 (2011).
Dangas, G. D. et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J. Am. Coll. Cardiol. 54, 1438–1446 (2009).
Lincoff, A. M. et al. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. JACC. Cardiovasc. Interv. 6, 639–648 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E. R. Bates has acted as a consultant for AstraZeneca, Eli Lilly, and Sanofi-Aventis. D. S. Menees declares no competing interets.
Rights and permissions
About this article
Cite this article
Menees, D., Bates, E. Antithrombotic drug and stent choices in primary PCI. Nat Rev Cardiol 8, 483–484 (2011). https://doi.org/10.1038/nrcardio.2011.108
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2011.108
